Rare disease, health record-focused RDMD raises $3M

The Golden Gate in Bridge San Francisco
RDMD, a San Francisco-based CRO focused on rare diseases and personal health records, hauled in $3 million in a seed funding round. (iStock/Getty Images Plus/Getty Images)

San Francisco-based startup RDMD, which is focused on rare diseases and personal health records, reaped $3 million in a seed funding round.

Participating in the fundraising were Lux Capital, Village Global, First Round’s Healthcare Co-op, Garuda, Shasta Ventures and unidentified angel investors, the company said.

The funds will be used for developing the company’s platform, additional hiring and expanding the scope of rare diseases it targets.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“RDMD was born out of my own personal journey with a rare disease,” Onno Faber, founder and chairman, said in a statement. “We have since pioneered the development of a powerful platform that leverages deep data insights to empower rare disease research and drug development, as well as an application that allows patients to take the management of their disease into their own hands.”

The company’s platform converts and analyzes data from electronic health records to produce new “real-world” data, which are stored in RDMD’s regulatory compliant database. That information can then be used by biopharma or research partners to help find new pathways for clinical trials or for regulatory submission for a new product.

Current partnerships include the National Cancer Institute and the Children’s Tumor Foundation.

Suggested Articles

California clinical trial artificial intelligence startup Saama Technologies has teamed up with Big Pharma Pfizer.

Contract research organization Worldwide Clinical Trials has hired Mike Mencer as EVP and general manager of its early-phase services.

Getting the right patients into the right trial at the right time, and keeping them there, is a tough gig.